Will the UK (finally) increase drug prices?

President Trump’s May 12 Executive Order around Most-Favored-Nation drug pricing argues that countries outside the US need to raise their prices on pharmaceuticals saying that many other countries are “freeloading” and paying less than their share for pharmaceuticals. In response, pharmaceutical companies have increased prices in the UK and even threatened to “walk away” from…

Read More

How Sutter Health Uses AI Agents to Handle Patients’ Scheduling, Refills & Billing Questions

Sutter Health is rolling out Hyro’s AI agents, which give patients 24/7 support for things like scheduling, prescription refills and billing questions. These agents aim to make routine healthcare interactions faster and easier, while also freeing up staff to handle more complex cases and providing data insights to improve the overall patient experience. The post…

Read More

Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete?

Petrelintide posted Phase 2 results showing tolerability comparable to a placebo, but average weight loss that was less than what analysts expected. The Zealand Pharma drug, in development under a partnership with Roche, is a peptide engineered to activate the amylin receptor. The post Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals,…

Read More

How should family spillover effects be measured in HTA?

A paper by Campbell et al. (2024) provides some guidance. The authors developed a series of recommendations based on literature review, expert interviews and an expert workshop in order to support consistent and transparent evaluation and use of validated family spillover effects in health technology assessments (HTA) and cost-effectiveness analyses (CEA). The expert panel consisted…

Read More